| How to improve survival after diagnosis of gastric cancer? It's back to the drawing board |
| FM Muggia |
|
JCO Aug 1 1993: 1437–1438.
[PDF]
|
 |
| Autologous bone marrow transplantation in childhood cancer |
| JV Simone |
|
JCO Aug 1 1993: 1439–1440.
[PDF]
|
|
|
Adjuvant therapy after curative resection for gastric cancer: meta- analysis of randomized trials |
| |
J Hermans, JJ Bonenkamp, MC Boon, AM Bunt, S Ohyama, M Sasako, and CJ Van de Velde |
| |
JCO Aug 1 1993: 1441–1447.
[Abstract]
[PDF]
|
|
|
Intensively timed induction therapy followed by autologous or allogeneic bone marrow transplantation for children with acute myeloid leukemia or myelodysplastic syndrome: a Childrens Cancer Group pilot study |
| |
WG Woods, N Kobrinsky, J Buckley, S Neudorf, J Sanders, L Miller, D Barnard, D Benjamin, J DeSwarte, and D Kalousek |
| |
JCO Aug 1 1993: 1448–1457.
[Abstract]
[PDF]
|
|
|
High-dose chemotherapy and autologous bone marrow rescue followed by interstitial and external-beam radiotherapy in newly diagnosed pediatric malignant gliomas |
| |
RL Heideman, EC Douglass, RA Krance, J Fontanesi, JA Langston, RA Sanford, EH Kovnar, J Ochs, J Kuttesch, and JJ Jenkins |
| |
JCO Aug 1 1993: 1458–1465.
[Abstract]
[PDF]
|
|
|
Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment |
| |
GM Brodeur, J Pritchard, F Berthold, NL Carlsen, V Castel, RP Castelberry, B De Bernardi, AE Evans, M Favrot, and F Hedborg |
| |
JCO Aug 1 1993: 1466–1477.
[Abstract]
[PDF]
|
|
|
Etoposide in relapsed or refractory Wilms' tumor: a phase II study by the French Society of Pediatric Oncology and the United Kingdom Children's Cancer Study Group |
| |
F Pein, R Pinkerton, MF Tournade, M Brunat-Mentigny, G Levitt, G Margueritte, H Rubie, D Sommelet, A Thyss, and JM Zucker |
| |
JCO Aug 1 1993: 1478–1481.
[Abstract]
[PDF]
|
|
|
Myeloablative radiochemotherapy and hematopoietic stem-cell rescue in poor-prognosis Ewing's sarcoma |
| |
S Burdach, H Jurgens, C Peters, W Nurnberger, C Mauz-Korholz, D Korholz, M Paulussen, H Pape, D Dilloo, and E Koscielniak |
| |
JCO Aug 1 1993: 1482–1488.
[Abstract]
[PDF]
|
|
|
All-trans retinoic acid: tolerance and biologic effects in myelodysplastic syndrome |
| |
R Kurzrock, E Estey, and M Talpaz |
| |
JCO Aug 1 1993: 1489–1495.
[Abstract]
[PDF]
|
|
|
Phase IB clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma: clinical and immunologic effects |
| |
JA Sosman, GR Weiss, KA Margolin, FR Aronson, M Sznol, MB Atkins, K O'Boyle, RI Fisher, DH Boldt, and J Doroshow |
| |
JCO Aug 1 1993: 1496–1505.
[Abstract]
[PDF]
|
|
|
OVX1 radioimmunoassay complements CA-125 for predicting the presence of residual ovarian carcinoma at second-look surgical surveillance procedures |
| |
FJ Xu, YH Yu, L Daly, K DeSombre, L Anselmino, GM Hass, A Berchuck, JT Soper, DL Clarke-Pearson, and C Boyer |
| |
JCO Aug 1 1993: 1506–1510.
[Abstract]
[PDF]
|
|
|
Pilot trial of cisplatin, radiation, and WR2721 in carcinoma of the uterine cervix: a New York Gynecologic Oncology Group study |
| |
S Wadler, JJ Beitler, JS Rubin, H Haynes, F McGill, A Rozenblit, G Goldberg, C Cohen, J Speyer, and C Runowicz |
| |
JCO Aug 1 1993: 1511–1516.
[Abstract]
[PDF]
|
|
|
Management of hypocalcemic effects of WR2721 administered on a daily times five schedule with cisplatin and radiation therapy. The New York Gynecologic Oncology Group |
| |
S Wadler, H Haynes, JJ Beitler, G Goldberg, JF Holland, H Hochster, H Bruckner, J Mandeli, H Smith, and C Runowicz |
| |
JCO Aug 1 1993: 1517–1522.
[Abstract]
[PDF]
|
|
|
Hydroxyurea versus misonidazole with radiation in cervical carcinoma: long-term follow-up of a Gynecologic Oncology Group trial |
| |
FB Stehman, BN Bundy, G Thomas, HM Keys, G d'Ablaing, 3d, WC Fowler, Jr, R Mortel, and WT Creasman |
| |
JCO Aug 1 1993: 1523–1528.
[Abstract]
[PDF]
|
|
|
Phase II study of goserelin for patients with postmenopausal metastatic breast cancer |
| |
T Saphner, AB Troxel, DC Tormey, D Neuberg, NJ Robert, KJ Pandya, JH Edmonson, RJ Rosenbluth, and MD Abeloff |
| |
JCO Aug 1 1993: 1529–1535.
[Abstract]
[PDF]
|
|
|
Impact of axillary lymph node dissection on the therapy of breast cancer patients |
| |
PP Lin, DC Allison, J Wainstock, KD Miller, WC Dooley, N Friedman, and RR Baker |
| |
JCO Aug 1 1993: 1536–1544.
[Abstract]
[PDF]
|
|
|
Contralateral breast cancer: clinical characteristics and impact on prognosis |
| |
EA Healey, EF Cook, EJ Orav, SJ Schnitt, JL Connolly, and JR Harris |
| |
JCO Aug 1 1993: 1545–1552.
[Abstract]
[PDF]
|
|
|
Prognostic factors in Waldenstrom's macroglobulinemia: a report of 167 cases |
| |
T Facon, M Brouillard, A Duhamel, P Morel, M Simon, JP Jouet, F Bauters, and P Fenaux |
| |
JCO Aug 1 1993: 1553–1558.
[Abstract]
[PDF]
|
|
|
Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B |
| |
AP Chahinian, K Antman, M Goutsou, JM Corson, Y Suzuki, C Modeas, JE Herndon, 2d, J Aisner, RR Ellison, and L Leone |
| |
JCO Aug 1 1993: 1559–1565.
[Abstract]
[PDF]
|
|
|
Flutamide withdrawal syndrome: its impact on clinical trials in hormone- refractory prostate cancer |
| |
HI Scher and WK Kelly |
| |
JCO Aug 1 1993: 1566–1572.
[Abstract]
[PDF]
|
|
|
EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma |
| |
WH Wilson, G Bryant, S Bates, A Fojo, RE Wittes, SM Steinberg, DR Kohler, ES Jaffe, J Herdt, and BD Cheson |
| |
JCO Aug 1 1993: 1573–1582.
[Abstract]
[PDF]
|
|
|
Use of peripheral-blood progenitor cells abrogates the myelotoxicity of repetitive outpatient high-dose carboplatin and cyclophosphamide chemotherapy |
| |
I Tepler, SA Cannistra, E Frei, 3d, R Gonin, KC Anderson, G Demetri, J Niloff, H Goodman, H Muntz, and M Muto |
| |
JCO Aug 1 1993: 1583–1591.
[Abstract]
[PDF]
|
|
|
Importance of clinical staging in limited small-cell lung cancer: a valuable system to separate prognostic subgroups. The University of Toronto Lung Oncology Group |
| |
FA Shepherd, RJ Ginsberg, R Haddad, R Feld, U Sagman, WK Evans, G DeBoer, and E Maki |
| |
JCO Aug 1 1993: 1592–1597.
[Abstract]
[PDF]
|
|
|
Extended administration of oral etoposide and oral cyclophosphamide for the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study |
| |
SM Grunberg, J Crowley, R Livingston, I Gill, SK Williamson, T O'Rourke, T Braun, ME Marshall, JK Weick, and SP Balcerzak |
| |
JCO Aug 1 1993: 1598–1601.
[Abstract]
[PDF]
|
|
|
Phase I clinical and pharmacokinetic study of a 14-day infusion of etoposide in patients with lung cancer |
| |
H Minami, K Shimokata, H Saka, H Saito, Y Ando, K Senda, F Nomura, and S Sakai |
| |
JCO Aug 1 1993: 1602–1608.
[Abstract]
[PDF]
|
|
|
Phase I trial of low-dose, prolonged continuous infusion fluorouracil plus interferon-alfa: evidence for enhanced fluorouracil toxicity without pharmacokinetic perturbation |
| |
JA Sparano, S Wadler, RB Diasio, R Zhang, Z Lu, EL Schwartz, A Einzig, and PH Wiernik |
| |
JCO Aug 1 1993: 1609–1617.
[Abstract]
[PDF]
|
|
|
Dose-response study of alendronate sodium for the treatment of cancer- associated hypercalcemia |
| |
SR Nussbaum, RP Warrell, Jr, R Rude, J Glusman, JP Bilezikian, AF Stewart, M Stepanavage, JF Sacco, SD Averbuch, and BJ Gertz |
| |
JCO Aug 1 1993: 1618–1623.
[Abstract]
[PDF]
|
|
| The epipodophyllotoxins: both sides of the coin |
| GK Rivera, CH Pui, and WM Crist |
|
JCO Aug 1 1993: 1624–1625.
[PDF]
|
|
| Additional cases of postchemotherapy rheumatism |
| DE Smith |
|
JCO Aug 1 1993: 1625–1626.
[PDF]
|
|
| Interleukin-2-induced thyroid dysfunction is correlated with treatment duration but not with tumor response |
| R Vassilopoulou-Sellin and A Sella |
|
JCO Aug 1 1993: 1626a.
[PDF]
|
|
| Testicular tumors, abdominal radiotherapy, and superior mesenteric artery syndrome |
| FE Klee, BR Osswald, and S Wysocki |
|
JCO Aug 1 1993: 1626b–1627.
[PDF]
|
|
